Microemulsions and nanoemulsions for targeted drug delivery to the brain

Current Nanoscience

Volumn 7, Issue 1, 2011, Pages 119-133

  Shinde, Rajshree L ^a   Jindal, Anil B ^a   Devarajan, Padma V ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Blood brain barrier; Brain targeting; Microemulsion; Nanoemulsion; Nose to brain delivery

Indexed keywords

ABSORPTION-ENHANCERS; BARRIER LIMIT; BLOOD-BRAIN BARRIER; BRAIN CANCER; BRAIN DELIVERY; BRAIN DISORDERS; CO-SURFACTANTS; DRUG CONCENTRATION; EFFLUX TRANSPORTER; ENDOTHELIAL SYSTEMS; INTRANASAL; NANO-EMULSIONS; NANOCARRIERS; NANOEMULSION; NEUROLOGICAL DISORDERS; NOSE TO BRAIN DELIVERY; PASSIVE DIFFUSIONS; RECEPTOR-MEDIATED ENDOCYTOSIS; SOLID LIPID NANOPARTICLES; STEALTH AGENTS; TARGETED DRUG DELIVERY; THERAPEUTIC APPLICATION;

BLOOD; CARRIER CONCENTRATION; DRUG DELIVERY; EMULSIFICATION; LIPOSOMES; PHOSPHOLIPIDS; SURFACE ACTIVE AGENTS;

MICROEMULSIONS;

BREAST CANCER RESISTANCE PROTEIN; CABERGOLINE; CARRIER PROTEIN; CLONAZEPAM; COSURFACTANT; DIACYLGLYCEROL; ETOPOSIDE; EXCIPIENT; GLYCOPROTEIN P; LIPID; LIPOSOME; MACROGOL; MONOACYLGLYCEROL; MORPHINE; MULTIDRUG RESISTANCE PROTEIN; NANOCARRIER; NIMODIPINE; OIL; OLANZAPINE; POLOXAMER; POLYSORBATE 80; POLYUNSATURATED FATTY ACID; RISPERIDONE; SOLID LIPID NANOPARTICLE; SUMATRIPTAN; SURFACTANT; TRIACYLGLYCEROL; UNINDEXED DRUG; WATER; ZOLMITRIPTAN;

ADSORPTION; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; BRAIN DISEASE; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; ENDOCYTOSIS; HUMAN; MICROEMULSION; NANOEMULSION; NONHUMAN; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM;

EID: 79551717683     PISSN: 15734137     EISSN: None     Source Type: Journal    
DOI: 10.2174/157341311794480282     Document Type: Article

References (261)

1. Statistics: Brain cancer Cancer registry reports, South Australia Dept. Health Globocan 2002 IARC. http://www.cancersa.org.au Updated March 2009.
2. Laquintana, V.; Trapani, A.; Denora, N.; Wang, F.; Gallo, J.M.; Trapani, G. New strategies to deliver anticancer drugs to brain tumors. Expert Opin. Drug Deliv., 2009, 6(10), 1017-1032.
3. Dabholkar, R.D.; Sawant, R.M.; Mongay, D.A.; Devarajan, P.V.; Torchilin, V.P. Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: Some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux. Int. J. Pharm., 2006, 315, 148-157.
4. Batrakova, E.V.; Li, S.; Alakhov, V.Y.; Miller, D.W.; Kabanov, A.V. Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J. Pharmacol. Exp. Ther., 2003, 304, 845-854.
5. Kreuter, J.; Ramge, P.; Petrov, V.; Hamm, S.; Gelprina, S.E.; Engelhardt, B.; Alyautdin, R.; von Briesen, H.; Begley, D. J. Direct evidence that polysorbate-80-coated poly(butyl cyanoacrylate) nanopaticles deliver drugs to the CNS via specific mechanisms requiring prior binding of the drug to the nanoparticles. Pharm. Res., 2003, 20, 409-416.
6. Zara, G.P.; Cavalli, R.; Bargoni, A.; Fundaro, A.; Vighetto, D.; Gasco, M.R. Intravenous administration to rabbits of nonstealth and stealth doxorubicinloaded solid lipid nanoparticles at increasing concentrations of stealth agents: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J. Drug Target., 2002, 10(4), 327-335.
7. Schnyder, A.; Huwyler, J. Drug transport to brain with targeted liposomes. NeuroRx, 2005, 2(1), 99-107.
8. Razdan, R.; Devarajan, P.V. Microemulsions. Indian Drugs, 2003, 40(3), 139-146.
9. Solans, C.; Izquierdo, P.; Nolla, J.; Azemar, N.; Garcia-Celma, M.J. Nanoemulsions. Curr. Opin. Colloid Interface Sci., 2005, 10, 102-110.
10. Lawrence, M.J.; Rees, G.D. Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev., 2000, 45, 89-121.
11. Araya, H.; Tomita, M.; Hayashi, M. The novel formulation design of O/W microemulsion for improving the gastrointestinal absorption of poorly water soluble compounds. Int. J. Pharm., 2005, 305(1-2), 61-74.
12. Sarciaux, J.M.; Acar, L.; Sado, P.A. Using microemulsion formulations for oral drug delivery of therapeutic peptides. Int. J. Pharm., 1995, 120(2), 127-136.
13. Hwang, S.R.; Lim, S.J.; Park, J.S.; Kim, C-K. Phospholipid-based microemulsion formulation of all-trans-retinoic acid for parenteral administration. Int. J. Pharm., 2004, 276(1-2), 175-183.
14. Li, L.; Nandi, I.; Kim, K.H. Development of an ethyl laurate-based microemulsion for rapid-onset intranasal delivery of diazepam. Int. J. Pharm., 2002, 237(1-2), 77-85.
15. Zhao, X.; Liu, J.P.; Zhang, X.; Li, Y. Enhancement of transdermal delivery of theophylline using microemulsion vehicle. Int. J. Pharm., 2006, 327(1-2), 58-64.
16. Kapoor, Y.; Chauhan, A. Ophthalmic delivery of Cyclosporine A from Brij-97 microemulsion and surfactant-laden p-HEMA hydrogels. Int. J. Pharm., 2008, 361(1-2), 222-229.
17. Jogani, V.V.; Shah, P.J.; Mishra, P.; Mishra A.K.; Misra, A.R. Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. Alzheimer Dis. Assoc. Disord., 2008, 22(2), 116-124.
18. Vyas, T.K.; Shahiwala, A.; Amiji, M.M. Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. Int. J. Pharm., 2008, 347(1-2), 93-101.
19. Deeken, J.F.; Loscher, W. The blood brain barrier and cancer: transport, treatment and torjan horses. Clin. Cancer. Res., 2007, 13(6), 1663-1674.
20. Kaur, I.P.; Bhandari, R.; Bhandari, S.; Kakkar, V. Potential of solid lipid nanoparticles in brain targeting. J. Control. Release, 2008, 127, 97-109.
21. Kondoh, M.; Yoshida, T.; Kakutani, H.; Yagi, K. Targeting tight junction proteins-significance for drug development. Drug Discov. Today, 2008, 13(3-4), 180-186.
22. Schneeberger, E.E.; Lynch, R.D. Structure, function, and regulation of cellular tight junctions. Am. J. Physiol., 1992, 262(6 Pt 1), L647-L661.
23. Furuse, M.; Tsukita, S. Claudins in occluding junctions of humans and flies. Trends Cell Biol., 2006, 16(4), 181-188.
24. Furuse, M.; Hirase, T.; Itoh, M.; Nagafuchi, A.; Yonemura, S.; Tsukita, S.; Tsukita, S. Occludin: A novel integral membrane protein localizing at tight junctions. J. Cell Biol., 1993, 123(6 Pt 2), 1777-1788.
25. Hirase, T.; Staddon, J.M.; Saitou, M.; Ando-Akatsuka, Y.; Itoh, M.; Furuse, M.; Fujimoto, K.; Tsukita, S.; Rubin, L.L. Occludin as a possible determinant of tight junction permeability in endothelial cells. J. Cell Sci., 1997, 110(14), 1603-1613.
26. Furuse, M.; Fujita, K.; Hiiragi, T.; Fujimoto, K.; Tsukita, S. Claudin-1 and -2: Novel integral membrane proteins localizing at tight junctions with no sequence similarity to occluding. J. Cell Biol., 1998, 141(7), 1539-1550.
27. Morita, K.; Furuse, M.; Fujimoto, K.; Tsukita, S. Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc. Natl. Acad. Sci. USA, 1999, 96(2), 511-516.
28. Tsukita, S.; Furuse, M. Occludin and claudins in tight-junction strands: Leading or supporting players? Trends Cell Biol., 1999, 9(7), 268-273.
29. Johnson, P.H.; Frank, D.; Costantino, H.R. Discovery of tight junction modulators: significance for drug development and delivery. Drug Discov. Today, 2008, 13(5-6), 261-267.
30. Lapierre, L.A. The molecular structure of the tight junction. Adv. Drug Deliv. Rev., 2000, 41, 255-264.
31. Cecchell, R.; Berezowski, V.; Lundquis, S.; Culot, M.; Renftel, M.; Dehouck, M.P.; Fenart, L. Modelling of the blood-brain barrier in drug discovery and development, Nat. Rev. Drug Discov., 2007, 6, 650-661.
32. Butt, A.M.; Jones, H.C.; Abbott, N.J. Electrical resistance across the bloodbrain barrier in anaesthetized rats: a developmental study. J. Physiol., 1990, 429, 47-62.
33. Hirase, T.; Staddon, J.M.; Saitou, M.; Ando-Akatsuka, Y.; Itoh, M.; Furuse, M.; Fujimoto, K.; Tsukita, S.; Rubin, L.L. Occludin as a possible determinant of tight junction permeability in endothelial cells. J. Cell Sci., 1997, 110(14), 1603-1613.
34. Lee, G.; Dallas, S.; Hong, M.; Bendayan, R. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol. Rev., 2001, 53, 569-596.
35. Segal, M.B. The choroid plexuses and the barriers between the blood and the cerebrospinal fluid. Cell. Mol. Neurobiol., 2000, 20, 183-196.
36. Alavijeh, M.S.; Chishty, M.; Qaiser, M.Z.; Palmer, A.M. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. NeuroRx, 2005, 2(4), 554-571.
37. Levin, V.A.; Patlak, C.S.; Landahl, H.D. Heuristic modeling of drug delivery to malignant brain tumors. J. Pharmacokinet. Biopharm., 1980, 8(3), 257-296.
38. Di, L.; Kerns, E.H.; Bezar, I.F.; Petusky, S.L.; Huang, Y. Comparison of blood-brain barrier permeability assays: In Situ brain perfusion, MDR1-MDCKII and PAMPA-BBB. J. Pharm. Sci., 2009, 98(6), 1980-1991.
39. Pardridge, W.M.; Mietus, L.J. Transport of steroid hormones through the rat blood-brain barrier. Primary role of albumin-bound hormone. J. Clin. Invest., 1979, 64, 145-154.
40. Diamond, J.M.; Wright, E.M. Molecular forces governing non-electrolyte permeation through cell membranes. Proc. R. Soc. Lond. B. Biol. Sci., 1969, 171, 273-316.
41. Fischer, H.; Gottschlich, R.; Seelig, A. Blood-brain barrier permeation: molecular parameters governing passive diffusion. J. Membr. Biol., 1998, 165, 201-211.
42. Pardridge, W.M. Blood-brain barrier delivery. Drug Discov. Today, 2007, 12(1-2), 54-61.
43. Pardridge, W.M. Blood-brain barrier drug targeting: the future of brain drug development. Mol. Interv., 2003, 3, 90-105, 51.
44. Golden, P.L.; Pollack, G.M. Blood-brain barrier efflux transport. J. Pharm. Sci., 2003, 92, 1739-1753.
45. Cornford, E.M.; Hyman, S. Blood-brain barrier permeability to small and large molecules. Adv. Drug Deliv. Rev., 1999, 36, 145-163.
46. Pardridge, W.M. Blood-brain barrier biology and methodology. J. Neurovirol., 1999, 5, 556-569.
47. Spector, R. Drug transport in the mammalian central nervous system: multiple complex systems. A critical analysis and commentary. Pharmacology, 2000, 60, 58-73.
48. Tsuji, A.; Tamai, I. Carrier-mediated or specialized transport of drugs across the blood-brain barrier. Adv. Drug Deliv. Rev., 1999, 36, 277-290.
49. Loscher, W.; Potschka, H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol., 2005, 76, 22-76.
50. Hediger, M.A; Romero, M.F.; Peng, J.P.; Rolfs, A.; Takanaga, H.; Bruford, E.A. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins introduction. Pflugers. Arch., 2004, 447(5), 465-468
51. Fricker, G.; Miller, D.S. Modulation of drug transporters at the blood-brain barrier. Pharmacology, 2004, 70, 169-176.
52. Halmos, T.; Santarromana, M.; Antonakis, K.; Scherman, D. Synthesis of glucose-chlorambucil derivatives and their recognition by the human GLUT1 glucose transporter. Eur. J. Pharm., 1996, 318, 477-484.
53. Gynther, M.; Laine, K.; Ropponen, J.; Leppänen, J.; Mannila, A.; Nevalainen, T.; Savolainen, T.; Järvinen, T.; Rautio, J. Large amino acid transporter enables brain delivery via prodrugs. J. Med. Chem., 2008, 51, 932-936.
54. Cornford, E.M.; Oldendorf, W.H. Independent blood-brain barrier transport systems for nucleic acid precursors. Biochim. Biophys. Acta, 1975, 394, 211-219.
55. Cornford, E.M.; Young, D.; Paxton, J.W.; Finlay, G.J.; Wilson, W.R.; Pardridge, W.M. Melphalan penetration of the blood-brain barrier via the neutral aminoacid transporter in tumor-bearing brain. Cancer Res., 1992, 52, 138-143.
56. Sakaeda, T.; Siahaan, T.J.; Audus, K.L.; Stella, V.J. Enhancement of transport of D-melphalan analogue by conjugation with L-glutamate across bovine brain microvessels endothelial cell monolayers. J. Drug Target, 2000, 8, 195-204.
57. Khalil, I.A.; Kogure, K.; Akita, H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol. Rev., 2006, 58, 32-45.
58. Pelkmans, L.; Kartenbeck, J.; Helenius, A. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat. Cell Biol., 2001, 3, 473-483.
59. Soni, V.; Kohli, D.; Jain, S.K. Transferrin-conjugated liposomal system for improved delivery of 5-fluorouracil to brain. J. Drug Target., 2008, 16, 73-78.
60. Coloma, M.J.; Lee, H.J.; Kurihara, A.; Landaw, E.M.; Boado, R.J.; Morrison, S.L.; Pardridge, W.M. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm. Res., 2000, 17(3), 266-274.
61. Nikanjam, M.; Blakely, E.A.; Bjornstad, K.A.; Shu, X.; Budinger, T.F.; Forte, T.M. Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int. J. Pharm., 2007, 328(1), 86-94.
62. Gaillard, P.J.; Brink, A.; de Boer, A.G. Deptheria toxin receptor targeted brain drug delivery. Int. Congress Series, 2005, 1277, 185-198.
63. Mirko, R.; Rita, F.; Luis Del, V.; Sergio, P.; Laura, S.; Rocco, M.; Micol, G.; Marianna, T.; Gian Luigi, C.; Eva, S. Leptin and its receptor are overexpressed in brain tumors and correlate with the degree of malignancy. Brain Pathol., 2010, 20(2), 481-489.
64. Batistatou, A.; Stefanou, D.; Goussia, A.; Arkoumani, E.; Papavassiliou, A.G.; Agnantis, N.J. Estrogen receptor beta (ERbeta) is expressed in brain astrocytic tumors and declines with dedifferentiation of the neoplasm. J. Cancer Res. Clin. Oncol., 2004, 130(7), 405-410.
65. Lu, Y.; Low, P.S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev., 2002, 54, 675-693.
66. Joshi, B.H.; Leland, P.; Asher, A.; Prayson, R.A.; Varricchio, F.; Puri, R.K. In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures. Cancer Res., 2001, 61(22), 8058-8061.
67. Madhankumar, A.B.; Slagle-Webb, B.; Mintz, A.; Sheehan, J.M.; Connor, J.R. Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme. Mol. Cancer Ther., 2006, 5, 3162-3169.
68. Kusuhara, H.; Sugiyama, Y. Efflux transport systems for drugs at the bloodbrain barrier and blood-cerebrospinal fluid barrier (part 1). Drug Discov. Today, 2001, 6, 150-156.
69. Schinkel, A.H. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug Deliv. Rev., 1999, 36, 179-194.
70. Fromm, M.F. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci., 2004, 25(8), 423-429.
71. Demeule, M.; Regina, A.; Jodoin, J.; Laplante A.; Dagenais, C.; Berthelet, F.; Moghrabi, A.; Béliveau, R. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul. Pharmacol., 2002, 38(6), 339-348.
72. Scherrmann, J.M. Expression, upregulation and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res., 2004, 64, 3296-3301.
73. Eisenblatter, T.; Huwel, S.; Galla, H.J. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the bloodbrain barrier. Brain Res., 2003, 971, 221-231.
74. Cooray, H.C.; Blackmore, C.G.; Maskell, L.; Barrand, M.A. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport., 2002, 13, 2059-2063.
75. Ito, K.; Suzuki, H.; Horie, T.; Sugiyama, Y. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm. Res., 2005, 22(10), 1559-1577.
76. Schinkel, A.H.; Jonker, J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev., 2003, 55, 3-29.
77. Cisternino, S.; Mercier, C.; Bourasset, F.; Roux, F.; Scherrmann, J.M. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res., 2004, 64(9), 3296-3301.
78. Kruh, G.D.; Belinsky, M.G. The MRP family of drug efflux pumps. Oncogene, 2003, 22(47), 7537-7552.
79. Löscher, W.; Potschka, H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci., 2005, 6(8), 591-602.
80. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. The multidrug resistance protein family. Biochim. Biophys. Acta, 1999, 1461, 347-357.
81. Rao, K.S.; Reddy, M.K.; Horning, J.L.; Labhasetwar, V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials, 2008, 29(33), 4429-4438.
82. Emmanuelle, B.; Ceile, B.; Peggy, M.; Salvatore, C.; Philippe, C.; Jean-Michel, S.; Jamal, T. Peptide-vector strategy bypasses P-glycoprotein efflux, and enhanced brain transport and solubility of paclitaxel. Anti-cancer Drugs, 2004, 15(10), 947-954.
83. Rousselle, C.; Clair, P.; Lefauconnier, J.M.; Kaczorek, M.; Scherrmann, J.M.; Temsamani, J. New Advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol. Pharmacol., 2000, 57, 679-686.
84. Rousselle, C.; Smirnova, M.; Clair, P; Lefauconnier, J.M.; Chavanieu, A.; Calas, B.; Scherrmann, J.M.; Temsamani, J. Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity. J. Pharmacol. Exp. Ther., 2001, 296, 124-131.
85. Ying, X.; Wen, H.; Lu, W.L.; Du, J.; Guo, J.; Tian, W.; Men, Y.; Zhang, Y.; Li, R.J.; Yang, T.Y.; Shang, D.W.; Lou, J.N.; Zhang, L.R.; Zhang, Q. Dualtargeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J. Control. Release, 2010, 141, 183-192.
86. Koukourakis, M.I.; Koukouraki, S.; Fezoulidis, I.; Kelekis, N.; Kyrias, G.; Archimandritis, S.; Karkavitsas, N. High intratumoural accumulation of stealtḧ liposomal doxorubicin (Caelyẍ) in glioblastomas and in metastatic brain tumours. Br. J. Cancer., 2000, 83(10), 1281-1286.
87. Du, J.; Lu, W.L.; Ying, X.; Liu, Y.; Du, P.; Tian, W.; Men, Y.; Guo, J.; Zhang, Y.; Li, R.J.; Zhou, J.; Lou, J.N.; Wang, J.C.; Zhang, X.; Zhang, Q. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals. Mol. Pharm., 2009, 6(3), 905-1017.
88. Doi, A.; Kawabata, S.; Iida, K.; Yokoyama, K.; Kajimoto, Y.; Kuroiwa, T.; Shirakawa, T.; Kirihata, M.; Kasaoka, S.; Maruyama, K.; Kumada, H.; Sakurai, Y.; Masunaga, S.; Ono, K.; Miyatake, S. Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy. J. Neurooncol., 2008, 87(3), 287-294.
89. Schnyder, A.; Krähenbühl, S.; Drewe, J.; Huwyler, J. Targeting of daunomycin using biotinylated immunoliposomes: pharmacokinetics, tissue distribution and in vitro pharmacological effects. J. Drug Target., 2005, 13(5), 325-335.
90. Soni, V.; Kohli, D.V.; Jain, S.K. Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-florouracil. J. Drug Target., 2005, 13(4), 245-250.
91. Zhang, X.; Xie, J.; Li, S.; Wang, X.; Hou, X. The study on brain targeting of the amphotericin B liposomes. J. Drug Target., 2003, 11(2), 117-122.
92. Ko, Y.T.; Bhattacharya, R.; Bickel, U. Liposome encapsulated polyethylenimine/ODN polyplexes for brain targeting. J. Control. Release, 2009, 133(3), 230-237.
93. Kakinuma, K.; Tanaka, R.; Takahashi, H.; Watanabe, M.; Nakagawa, T.; Kuroki, M. Targeting chemotherapy for malignant brain tumor using thermosensitive liposome and localized hyperthermia. J. Neurosurg., 1996, 84(2), 180-184.
94. Rivière, C.; Martina, M.S.; Tomita, Y.; Wilhelm, C.; Tran, D.A.; Ménager, C.; Pinard, E.; Lesieur, S.; Gazeau, F.; Seylaz, J. Magnetic targeting of nanometric magnetic fluid loaded liposomes to specific brain intravascular areas: a dynamic imaging study in mice. J. Radiol., 2007, 244(2), 439-448.
95. Saiyed, Z.M.; Gandhi, N.H.; Nair, M.P. Magnetic nanoformulation of azidothymidine 5'-triphosphate for targeted delivery across the blood-brain barrier. Int. J. Nanomed., 2010, 5, 157-166.
96. Salmaso, S.; Pappalardo, J.S.; Sawant, R.R.; Musacchio, T.; Rockwell, K.; Caliceti, P.; Torchilin, V.P. Targeting glioma cells in vitro with ascorbateconjugated pharmaceutical nanocarriers. Bioconjug Chem., 2009, 20(12), 2348-2355.
97. Hülsermann, U.; Hoffmann, M.M.; Massing, U.; Fricker, G. Uptake of apolipoprotein E fragment coupled liposomes by cultured brain microvessel endothelial cells and intact brain capillaries. J. Drug Target., 2009, 17(8), 610-618.
98. Chen, H.; Tang, L.; Qin, Y.; Yin, Y.; Tang, J.; Tang, W.; Sun, X.; Zhang, Z.; Liu, J.; He, Q. Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery. Eur. J. Pharm. Sci., 2010, 40(2), 94-102.
99. Tamaru, M.; Akita, H.; Fujiwara, T.; Kajimoto, K.; Harashima, H. Leptinderived peptide, a targeting ligand for mouse brain-derived endothelial cells via macropinocytosis. Biochem. Biophys. Res. Commun., 2010, 394(3), 587-592.
100. Qin, Y.; Fan, W.; Chen, H.; Yao, N.; Tang, W.; Tang, J.; Yuan, W.; Kuai, R.; Zhang, Z.; Wu, Y.; He, Q. In vitro and in vivo investigation of glucosemediated brain-targeting liposomes. J. Drug Target., 2010, 18(7), 536-549.
101. Qin, J.; Chen, D.; Hu, H.; Qiao, M.; Zhao, X.; Chen, B. Body distributioin of RGD-mediated liposome in brain-targeting drug delivery. Yakugaku Zasshi., 2007, 127(9), 1497-1501.
102. Qin, J.; Chen, D.; Hu, H.; Cui, Q.; Qiao, M.; Chen, B. Surface modification of RGD-liposomes for selective drug delivery to monocytes/neutrophils in brain. Chem. Pharm. Bull. (Tokyo), 2007, 55(8), 1192-1197.
103. Jain, S.; Mishra, V.; Singh, P.; Dubey, P.K.; Saraf, D.K.; Vyas, S.P. RGDanchored magnetic liposomes for monocytes/neutrophils-mediated brain targeting. Int. J. Pharm., 2003, 261(1-2), 43-55.
104. Huwyler, J.; Wu, D.; Pardridge, W.M. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. USA, 1996, 93, 14164-14169.
105. Gupta, B.; Levchenko, T.S.; Mongayt, D.A.; Torchilin, V.P. Monoclonal antibody 2C5-mediated binding of liposomes to brain tumor cells in vitro and in subcutaneous tumor model in vivo. J. Drug Target., 2005, 13(6), 337-343.
106. Huwyler, J.; Yang, J.; Pardridge, W.M. Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat. J. Pharmacol. Exp. Ther., 1997, 282, 1541-1546.
107. Shi, N.; Boado, R.J.; Pardridge, W.M. Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. Pharm. Res., 2001, 18(8), 1091-1095.
108. Bargoni, A.; Cavalli, R.; Zara, G.P.; Fundarò, A.; Caputo, O.; Gasco, M.R. Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II-tissue distribution. Pharmacol. Res., 2001, 43, 497-502.
109. Zara, G.P.; Bargoni, A.; Cavalli, R.; Fundarò, A.; Vighetto, D.; Gasco, M.R. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J. Pharm. Sci., 2002, 91, 1324-1333.
110. Wang, J.X.; Sun, X.; Zhang, Z.R. Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles. Eur. J. Pharm. Biopharm., 2002, 54, 285-290.
111. Yang, S.C.; Lu, L.F.; Cai, Y.; Zhu, J.B.; Liang, B.W.; Yang, C.Z. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control. Release, 1999, 59, 299-307.
112. Fundaro, A.; Cavalli, R.; Bargoni, A.; Vighetto, D.; Zara, G.P.; Gasco, M.R. Non-stealth and stealth solid lipid nanoparticles (SLNs) carrying doxorubicin: pharmacokinetics and tissue distribution after I.V. administration to rats. Pharmacol. Res., 2000, 42, 337-343.
113. Chen, D.-B.; Yang, T.-Z.; Lu, W.-L.; Zhang, Q. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem. Pharm. Bull. (Tokyo), 2001, 49(11), 1444-1447.
114. Cavalli, R.; Caputo, O.; Gasco, M.R. Preparation and characterization of solid lipid nanospheres containing paclitaxel. Eur. J. Pharm. Sci., 2000, 10(4), 305-309.
115. Harivardhan Reddy, L.; Sharma, R.K.; Chuttani, K.; Mishra, A.K.; Murthy, R.S. Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. J. Control. Release, 2005, 105(3), 185-198.
116. Cavalli, R.; Bocca, C.; Miglietta, A.; Caputo, O.; Gasco, M.R. Albumin adsorption on stealth and non-stealth solid lipid nanoparticles. STP Pharma. Sci., 1999, 9, 183-189.
117. Goppert, T.M.; Müller, R. H. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. J. Drug Target., 2005, 13(3), 179-187.
118. Yang, S.C.; Zhu, J.B.; Lu, Y.; Liang, B.W.; Yang, C. Z. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm. Res. 1999, 16, 751-757.
119. Göppert, T.M.; Müller, R.H. Protein adsorption patterns on poloxamer-and poloxamine-stabilized solid lipid nanoparticles (SLN). Eur. J. Pharm. Biopharm., 2005, 60(3), 361-372.
120. Reddy, L.H.; Sharma, R.K.; Chuttani, K.; Mishra, A.K.; Murthy, R.R. Etoposide-incorporated tripalmitin nanoparticles with different surface charge: formulation, characterization, radiolabeling, and biodistribution studies. AAPS J., 2004, 6(3), 55-64.
121. Eccleston, G. In: Encyclopedia of Pharmaceutical Technology, Swarbrick, J.; Boylan, J.C., Eds.; Marcel Dekker: New York, 1995; vol. 9, pp. 375-421.
122. Karasulu, H.Y. Microemulsions as novel drug carriers: the formation, stability, applications and toxicity. Expert Opin. Drug Deliv., 2008, 5(1), 1-17.
123. Solans, C.; Izquierdo, P.; Nolla, J.; Azemar, N.; Garcia-Celma, M.J. Nanoemulsions. Curr. Opin. Colloid Interface Sci., 2005, 10, 102-110.
124. Tadros, T.; Izquierdo, P.; Esquena, J.; Solans, C. Formation and stability of nanoemulsions. Adv. Colloid Interface Sci., 2004, 109, 303-318.
125. Spernath, A.; Abrahim, A. Microemulsion as carrier for drugs and nutraceuticals. Adv. Colloid Interface Sci., 2006, 128-130, 47-64.
126. Lawrence, M.J.; Rees, G.D. Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev., 2000, 45, 89-121.
127. Ganta, S.; Devalapally, H; Baguley, B.C.; Garg, S.; Amiji, M. Microfluidic preparation of chlorambucil nanoemulsion formulations and evaluation of cytotoxicity and pro-apoptotic activity in tumor cells. J. Biomed. Nanotechnol., 2008, 4, 1-9.
128. Yilmaz, E.; Borchert, H.H. Design of a phytosphingosine-containing, positively-charged nanoemulsion as a colloidal carrier system for dermal application of ceramides. Eur. J. Pharm. Biopharm., 2005, 60(1), 91-98.
129. Shinoda, K., Saito, H. The Stability of O/W type emulsions as functions of temperature and the HLB of emulsifiers: The emulsification by PIT-method. J. Colloid Interface Sci., 1969, 30(2), 258-263.
130. Tenjarla, S. Microemulsion: an overview and pharmaceutical applications. Crit. Rev. Ther. Drug Carrier Syst., 1999, 16(5), 461-521.
131. Date, A.A.; Nagarsenker, M.S. Parenteral microemulsions: An overview. Int. J. Pharm., 2008, 355, 19-30.
132. Patravle, V.B.; Date, A.A. In: Microemulsions Background, New Concepts, Applications, Perspectives. Stubenrauch, C., Ed.; Wiley, John & Sons: Ireland, 2009, pp. 259-293.
133. Strickley, R.G. Solubilizing excipients in oral and injectable formulations. Pharm. Res., 2004, 21, 201-230.
134. Vandamme, T.F. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog. Retin. Eye. Res., 2002. 21, 15-34.
135. Malcolmson, C.; Sidhu, A.; Satra, C.; Kantaria, S.; Lawrence, M.J. Effect of the nature of oil on the incorporation of testosterone propionate into nonionic oil-in-water microemulsions. J. Pharm. Sci., 1998, 87, 109-116.
136. Warisnoicharoen, W.; Lansley, A.B.; Lawrence, M.J. Nonionic oil-in water microemulsions: the effect of oil type on phase behavior. Int. J. Pharm., 2000, 198, 7-27.
137. Constantinides, P.P.; Tustian, A.; Kessler, D.R. Tocol emulsions for drug solubilization and parenteral delivery. Adv. Drug Deliv. Rev., 2004, 56, 1243-1255.
138. Narang, A.S.; Delmarre, D.; Gao, D. Stable drug encapsulation in micelles and microemulsions. Int. J. Pharm., 2007, 345, 9-25.
139. Yu, C.; Meng, J.; Chen, J.; Tang, X. Preparation of ergoloid mesylate submicron emulsions for enhancing nasal absorption and reducing nasal ciliotoxicity. Int. J. Pharm., 2009, 375(1-2), 16-21.
140. Moreno, M.A.; Ballesteros, M.P.; Frutos, P. Lecithin-based oil-in-water microemulsions for parenteral use: pseudo ternary phase diagrams, characterization and toxicity studies. J. Pharm. Sci. 2003, 92, 1428-1437.
141. Bagwe, R.P.; Kanicky, J.R.; Palla, B.J.; Patanjali, P.K.; Shah, D.O. Improved drug delivery using microemulsions: rationale, recent progress, and new horizons. Crit. Rev. Ther. Drug Carrier Syst., 2001, 18, 77-140.
142. Owen, S.C. In: Handbook of Pharmaceutical Excipients, 5th ed.; Rowe, R. C.; Sheskey, P. J.; Weller, P.J., Eds.; Pharmaceutical Press: New York, 2006, pp. 18-20.
143. Sztriha, L.; Betz, A.L. Oleic acid reversibly opens the blood-brain barrier. Brain Res., 1991, 550, 257-262.
144. Barta, C.A; Sachs-Barrable, K.; Feng, F.; Wasan, K.M. Effcet of monoglycerides on P-glycoprotein: Modulation of activity and expression in caco-2 cell monolyers. Mol. Pharm., 2008, 5(5), 863-875.
145. Sachs-Barrable, K.; Thamboo, A.; Lee, S.D.; Wasan, K. M. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells. J. Pharm. Pharm. Sci., 2007, 10, 319-331.
146. Tamilvanan, S. Oil-in-water lipid emulsions: implications for parenteral and ocular delivery system. Prog. Lipid Res., 2004, 43(6) 489-533.
147. Tamilvanan, S. Formulation of multifunctional oil-in-water nanosized emulsions for active and passive targeting of drugs to otherwise inaccessible internal organs of the human body. Int. J. Pharm., 2009, 381, 62-76.
148. Lukiw, W.J, Docosahexaenoic acid and amyloid-β peptide signaling in Alzheimer's disease. World Rev. Nutr. Diet., 2009, 99, 55-70.
149. Neuringer, M.; Connor, W.E. The essentiality of n-3 fatty acids for the development and function of retina and brain. Ann. Rev. Nutr., 1988, 8, 517-541.
150. Lukiw, W.J.; Bazan, N.G. Docosahexaenoic acid and the aging brain. J. Nutr., 2008, 138, 2510-2514.
151. Chen, C.T.; Liu, Z.; Ouellet Calon, F.; Bazinet, R.P. Rapid β-oxidation of ecosapentaenoic acid in mouse brain: An in situ study. Prostaglandins Leukot. Essent. Fatty Acids, 2009, 80(2-3), 157-163.
152. Morris, M.C.; Evans, D.A.; Bienias, J.L.; Tangney, C.C.; Bennett, D.A.; Wilson, R.S.; Aggarwal, N.; Schneider, J. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch. Neurol., 2003, 60, 940-946.
153. Calon, F.; Lim, G.P.; Yang, F.; Morihara, T.; Teter, B.; Ubeda, O.; Rostaing, P.; Triller, A.; Salem, Jr N.; Ashe, K.H.; Frautschy, S.A.; Cole, G.M. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron, 2004, 43, 633-645.
154. Ganta, S.; Devalapally, H.; Baguley, B.C.; Garg, S; Amiji, M. Microfluidic preparation of chlorambucil nanoemulsion formulations and evaluation of cytotoxicity and pro-Apoptotic activity in tumor cells. J. Biomed. Nanotechnol., 2008, 4, 1-9.
155. Tiwari, S.; Tan, Y.-M.; Amiji, M. Preparation and in vitro characterization of multifunctional nanoemulsions for simultaneous. MR imaging and targeted drug delivery. J. Biomed. Nanotechnol., 2006, 2(3-4), 1-8.
156. Ganta, S.; Amiji, M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug mesistance in tumor cells. Mol. Pharm., 2009, 6(3), 928-939.
157. Watari, M.; Hamazaki, K.; Hirata, T.; Hamazaki, T.; Okubo, Y. Hostility of drug-free patients with schizophrenia and n-3 polyunsaturated fatty acid levels in red blood cells. Psychiatry Res., 2010, 177(1-2), 22-26.
158. Billman, G.E.; Kang, J.X.; Leaf, A. Prevention of ischemia-induced cardiac sudden death by n-3 polyunsaturated fatty acids in dogs. Lipids, 1997, 32(11), 1161-1168.
159. Bromfield, E.; Dworetzky, B.; Hurwitz, S.; Eluri, Z.; Lane, L.; Replansky, S.; Mostofsky, D. A randomized trial of polyunsaturated fatty acids for refractory epilepsy. Epilepsy Behav., 2008, 12(1), 187-190.
160. Farinotti, M.; Simi, S.; Di Pietrantonj, C.; McDowell, N.; Brait, L.; Lupo, D.; Filippini, G. Dietary interventions for multiple sclerosis. Cochrane Database Syst. Rev., 2007, 1, CD004192.
161. Dexter, D.T.; Carter, C.J.; Wells, F.R.; Javoy-Agid, F.; Agid, Y.; Lees, A.; Jenner, P.; Marsden, C.D. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem., 1989, 52(2), 381-389.
162. Edmond, J. Essential polyunsaturated fatty acids and the barrier to the brain: the components of a model for transport. J. Mol. Neurosci., 2001, 16, 181-193 (Discussion 215-121).
163. Sztriha, L.; Betz, A.L. Oleic acid reversibly opens the blood-brain barrier. Brain Res., 1991, 550, 257-262.
164. Cornaire, G.; Woodley, J.; Hermann, P.; Cloarec, A.; Arellano, C.; Houin, G. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int. J. Pharm., 2004, 278, 119-131.
165. Rege, B.D.; Kao, J.P.; Polli, J. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur. J. Pharm. Sci. 2002, 16(4-5), 237-246.
166. Collnot, E.M.; Baldes, C.; Wempe, M.F.; Hyatt, J.; Navarro, L.; Edgar, K.; Schaefer, U. F.; Lehr, C. M. Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. J. Control. Release., 2006, 11(1-2), 35-40.
167. Shen, Q.; Lin, Y.; Handa, T.; Doi, M.; Sugie, M.; Wakayama, K.; Okada, N.; Fujita, T.; Yamamoto, A. Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int. J. Pharm., 2006, 313(1-2), 49-56.
168. Hugger, E.D.; Novak, B.L.; Burton, P.S.; Audus, K.L.; Borchardt, R.T. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J. Pharm. Sci., 2002, 9(9), 1991-2002.
169. Shono, Y.; Nishihara, H.; Matsuda, Y.; Furukawa, S.; Okada, N.; Fujita, T.; Yamamoto, A. Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. J. Pharm. Sci., 2004, 93(4), 877-885.
170. Zordan-Nudo, T.; Ling, V.; Liu, Z.; Georges, E. Effects of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance. Cancer Res., 1993, 53(24), 5994-6000.
171. Batrakova, E.V.; Han, H.Y.; Alakhov, V.Y.; Miller, D.W.; Kabanov, A.V. Effects of Pluronic block copolymers on drug absorption in Caco-2 cell monolayers. Pharm. Res. 1998, 15(6), 850-855.
172. Lin, Y.; Shen, Q.; Katsumi, H.; Okada, N.; Fujita, T.; Jiang, X.; Yamamoto, A. Effects of Labrasol and other pharmaceutical excipients on the intestinal transport and absorption of rhodamine123, a P-glycoprotein substrate, in rats. Biol. Pharm. Bull. 2007, 30(7), 1301-1307.
173. Varma, M.V.; Panchagnula, R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur. J. Pharm. Sci., 2005, 25, 445-453.
174. Oyewumi, M.O.; Yokel, R.A.; Jay, M.; Coakley, T.; Mumper, R.J. Comparison of cell uptake, biodistribution and tumor retention of folate coated and PEG coated gadolinium nanoparticles in tumor bearing mice. J. Control. Release, 2004, 95(3) 613-626.
175. Wong, H.L.; Chattopadhyay, N.; Wu, X.Y.; Bendayan, R. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv. Drug Deliv. Rev., 2010, 62, 503-517.
176. Park, K-M.; Lee, M-K.; Hwang, K-J.; Kim, C-K. Phospholipid-based microemulsions of flurbiprofen by the spontaneous emulsification process. Int. J. Pharm., 1999, 183(2), 145-154.
177. Barchet, T.M.; Amiji, M.M. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases. Expert Opin. Drug Deliv., 2009, 6(3), 211-225.
178. Koo, Y.L.; Reddy, G.R.; Bhojani, M.; Schneider, R.; Philbert, M.A.; Rehemtulla, A.; Ross, B.D.; Kopelman, R. Brain cancer diagnosis and therapy with nanoplatforms. Adv. Drug Deliv. Rev., 2006, 58, 1556-1577.
179. Garcia, E.; Andrieux, K; Gil, S.; Couvreur, P. Colloidal carriers and bloodbrain barrier (BBB) translocation: A way to deliver drug to the brain? Int. J. Pharm., 2005, 298, 274-292.
180. Kreuter, J.; Shamenkov, D.; Petrov, V.; Ramge, P.; Cychutek, K.; Koch-Brandt, C.; Alyautdin, R. Apolipoprotein-mediated transport of nanoparticlebound drugs across the blood-brain barrier. J. Drug Target, 2002, 10, 317-325.
181. Ambruosi, A.; Gelperina, S.; Khalansky, A.; Tanski, S.; Theisen, A.; Kreuter, J. Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model. J. Microencapsul., 2006, 23, 582-592.
182. Kanwar, J.R.; Mahidhara, G.; Kanwar, R.K. Recent Advances in Nanoneurology for Drug Delivery to the Brain. Curr. Nanosci., 2009, 5, 441-448.
183. ® block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier. Adv. Drug Deliv. Rev., 2003, 55 (1), 151-164.
184. Bansal, T.; Akhtar, N.; Jaggi, M.; Khar, R.K.; Talegaonkar, S. Novel formulation approaches for optimizing delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov. Today, 2001, 14(21-22), 150-156.
185. Breedveld, P.; Beijnen, J.H.; Schellens, Jan, H.M. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol. Sci., 2006, 27(1), 17-24.
186. van Asperen, J.; van Tellingen, O.; van der Valk, M.A.; Rozenhart, M.; Beijnen, J.H. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin. Cancer Res., 1998, 4(10), 2293-2297.
187. Allen, J.D.; van Loevezijn, A.; Lakhai, J.M.; van der Valk, M.; van Tellingen, O.; Reid, G.; Schellens, J.H.; Koomen, G.J.; Schinkel, A.H. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol. Cancer Ther. 2002, 1(6), 417-425.
188. Zhang, S.; Yang, X.; Morris, M.E. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol. Pharmacol., 2004, 65, 1208-1216.
189. Bansal, T.; Jaggi, M.; Khar, R.K.; Talegaonkar, S. Emerging significance of flavonoids as P glycoprotein inhibitors in cancer chemotherapy. J. Pharm. Pharm. Sci., 2009, 12, 46-78.
190. Pang, Z.; Lu, W.; Gao, H.; Hu, K.; Chen, J.; Zhang, C.; Gao, X.; Jiang, X.; Zhu, C. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J. Control. Release, 2008, 128(2), 120-127.
191. Dias, M.L.N.; Carvalho, J.P.; Rodrigues, D.G.; Graziani, S.R.; Maranhao, R.C. Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers. Cancer Chemother. Pharmacol., 2007, 59, 105-111.
192. Valduga, C.J.; Fernandes, D.C.; Lo Prete, A.C.; Azevedo, C.H.; Rodrigues, D.G.; Maranhão, R.C. Use of a cholesterol-rich microemulsion that binds to low-density lipoproteins receptors as vehicle for etoposide. J. Pharm. Pharmacol., 2003, 55(12), 1615-1622.
193. Kanga, B.K.; Chonb, S.K.; Kimb, S.H.; Jeongc, S.Y.; Kimc, M.S.; Choc, S.H.; Leec, H.B.; Khanga, G. Controlled release of paclitaxel from microemulsion containing PLGA and evaluation of anti-tumor activity in vitro and in vivo. Int. J. Pharm., 2004, 286, 147-156.
194. Wacher, V.J.; Salphati, I.; Benet, L.Z. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliv. Rev., 1996, 20, 99-112.
195. Paine, M.F.; Shen, D.D.; Kunze, K.L.; Perkins, J.D.; Marsh, C.L.; McVicar, J.P.; Barr, D.M.; Gillies, B.S.; Thummel, K.E. First pass metabolism by the human intestine. Clin. Pharmacol. Ther., 1996, 60, 14-24.
196. Benet, L.Z.; Cummins, C.L.; Wu, C.Y. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int. J. Pharm., 2004, 277, 3-9.
197. Talegaonkar, S.; Azeem, A.; Ahmad, F.J.; Khar, R.K.; Pathan, S.A.; Khan, Z.I. Microemulsions: A Novel Approach to Enhanced Drug Delivery. Recent Pat. Drug Deliv. Formul., 2008, 2, 238-257.
198. Nornoo, A.O.; Zheng, H.; Lopes, L.B.; Johnson-Restrepo, B.; Kannan, K.; Reed, R. Oral microemulsions of paclitaxel: In situ and pharmacokinetic studies. Eur. J. Pharm. Biopharm., 2009, 71(2), 310-317.
199. Yin, Y.M.; Cui, F.D.; Mu, C.F.; Choi, M.K.; Kim, J.S.; Chung, S.J.; Shim, C.K.; Kim, D.D. Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. J. Control. Release, 2009, 140(2), 86-94.
200. Hirunpanich, V.; Sato, H. Improvement of cyclosporine A bioavailability by incorporating ethyl docosahexaenoate in the microemulsion as an oil excipient. Eur. J. Pharm. Biopharm., 2009, 73(2), 247-252.
201. Cui, J.; Yu, B.; Zhao, Y.; Zhu, W.; Li, H.; Lou, H.; Zhai, G. Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems. Int. J. Pharm., 2009, 371(1-2), 148-155.
202. Venkatesh, G.; Majid, M.I.; Mansor, S.M.; Nair, N.K.; Croft, S.L.; Navaratnam, V. In vitro and in vivo evaluation of self-microemulsifying drug delivery system of buparvaquone. Drug Dev. Ind. Pharm., 2010, 36(6), 735-745.
203. Bali, V.; Ali, M.; Ali, J. Study of surfactant combinations and development of a novel nanoemulsion for minimising variations in bioavailability of ezetimibe. Colloids Surfaces B Biointerfaces, 2010, 76(2), 410-420.
204. Sheikh, S.; Shakeel, F.; Talegaonkar, S.; Ahmad, F.J.; Khar, R.K.; Ali, M. Development and bioavailability assessment of ramipril nanoemulsion formulation Eur. J. Pharm. Biopharm., 2007, 66(2), 227-243.
205. Kuminek, G.; Kratz, J.M.; Ribeiro, R.; Kelmann, R.G.; de Araújo, B.V.; Teixeira, H.F.; Simões, C.M.O.; Koester, L.S. Pharmacokinetic study of a carbamazepine nanoemulsion in beagle dogs. Int. J. Pharm., 2009, 378(1-2), 146-148.
206. Brüsewitz, C.; Schendler, A.; Funke, A.; Wagner, T.; Lipp, R. Novel poloxamer-based nanoemulsions to enhance the intestinal absorption of active compounds. Int. J. Pharm., 2007, 329(1-2), 173-181.
207. Kim, S.K.; Lee, E.H.; Vaishali, B.; Lee, S.; Lee, Y-K.; Kim, C-Y.; Moon, H.T.; Byun, Y. Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates. J. Control. Release, 2005, 105(1-2) 32-42.
208. Çelebi, N.; Türkyilmaz, A.; Gönül, B.; Özogul, C. Effects of epidermal growth factor microemulsion formulation on the healing of stress-induced gastric ulcers in rats. J. Control. Release, 2002, 83(2), 197-210.
209. Constantinides, P.P. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm. Res., 1995, 12(11), 1561-1572.
210. Desai, A.; Vyas, T.; Amiji, M. Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations. J. Pharm. Sci., 2008, 97(7), 2745-2756.
211. Mistry, A.; Stolnik, S.; Illum, L. Nanoparticles for direct nose-to-brain delivery of drugs. Int. J. Pharm., 2009, 379, 146-157.
212. Costantino, H.R.; Illum, L.; Brandt, G.; Johnson, P.H.; Quay, S. C. Intranasal delivery: physicochemical and therapeutic aspects. Int. J. Pharm., 2007, 337(1-2), 1-24.
213. Illum, L. Is nose-to-brain transport of drugs in man a reality? J. Pharm. Pharmacol., 2004, 56(1), 3-17.
214. Morrison, E.E.; Costanzo, R.M. Morphology of olfactory epithelium in humans and other vertebrates. Microsc. Res. Tech., 1992, 23, 49-61.
215. Merkus, P.; Guchelaar, H-J.; Bosch, D.A.; Merkus, F.W. Direct access of drugs to the human brain after intranasal drug administration? Neurology, 2003, 60, 1669-1671.
216. Thorne, R.G.; Pronk, G.J.; Padmanabhan, V.; Frey, W.H. Delivery of insulin-like growth factor-i to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience, 2004, 127, 481-496.
217. Mygind, N.; Dahl, R. Anatomy, physiology and function of the nasal cavities in health and disease. Adv. Drug Deliv. Rev., 1998, 29(1-2), 3-12.
218. Javaid, J.I.; Davis, J.M. Cocaine disposition in discrete regions of rat brain. Biopharm. Drug Dispos., 1993, 14, 357-364.
219. Chow, H.S.; Chen, Z.; Natsuura, G.T. Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats. J. Pharm. Sci. 1999, 88, 754-758.
220. Char, H.; Kumar, S.; Patel, S.; Piemontese, D.; Iqbal, K.; Malick, A.W.; Salvador, R.A.; Behl, C.R. Nasal delivery of [14C]dextromethorphan hydrochloride in rats: levels in plasma and brain. J. Pharm. Sci., 1992, 81, 750-752.
221. Seki, T.; Sato, N.; Hasegawa, T.; Kawaguchi, T.; Juni, K. Nasal absorption of zidovudine and its transport to cerebrospinal fluid in rats. Biol. Pharm. Bull., 1994, 17, 1135-1137.
222. Kao, H.D.; Traboulsi, A.; Itoh, S.; Dittert, L.; Hussain, A. Enhancement of the systemic and CNS specific delivery of l-Dopa by the nasal administration of its water soluble prodrugs. Pharm. Res., 2000, 17, 978-984.
223. Chow, H.H.; Anavy, N.; Villalobos, A. Direct nose-brain transport of benzoylecgonine following intranasal administration in rats. J. Pharm. Sci., 2001, 90, 1729-1735.
224. Al-Ghananeem, A.M.; Traboulsi, A.A.; Dittert, L.W.; Hussain, A.A. Targeted brain delivery of 17 beta-estradiol via nasally administered water soluble prodrugs. AAPS PharmSciTech, 2002, 3, E5.
225. Barakat, N.S.; Omar, S.A.; Ahmed, A.A. Carbamazepine uptake into rat brain following intra-olfactory transport. J. Pharm. Pharmacol., 2006, 58, 63-72.
226. Johnson, N.J.; Hanson, L.R.; Frey, W.H. Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures. Mol. Pharm., 2010, 7(3), 884-893.
227. Gizurarson, S.; Thorvaldsson, T.; Sigurdsson, P.; Gunnarsson, E. Selective delivery of insulin into the brain: intraolfactory absorption. Int. J. Pharm., 1996, 140, 77-83.
228. Dufes, C.; Olivier, J.C.; Gaillard, F.; Gaillard, A.; Couet, W.; Muller, J.M. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration in rats. Int. J. Pharm., 2003, 255, 87-97.
229. Thorne, R.G.; Pronk, G.J.; Padmanabhan, V.; Frey, W.H. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience, 2004, 127, 481-496.
230. Pietrowsky, R.; Struben, C.; Molle, M.; Fehm, H.L.; Born, J. Brain potential changes after intranasal vs. intravenous administration of vasopressin: evidence for a direct nose-brain pathway for peptide effects in humans. Biol. Psychiatry, 1996, 39, 332-340.
231. Derad, I.; Willeke, K.; Pietrowsky, R.; Born, J.; Fehm, H.L. Intranasal angiotensin II directly influences central nervous regulation of blood pressure. Am. J. Hypertens., 1998, 11, 971-977.
232. Sakane, T.; Akizuki, M.; Yamashita, S.; Sezaki, H.; Nadai, T. Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the molecular weight of drugs. J. Pharm. Pharmacol., 1995, 47, 379-381.
233. Sakane, T.; Akizuki, M.; Yamashita, S.; Sezaki, H.; Nadai, T. The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug. Chem. Pharm. Bull., 1991, 39, 2456-2458.
234. Sakane, T.; Akizuki, M.; Yamashita, S.; Sezaki, H.; Nadai, T. Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the dissociation of the drug. J. Pharm. Pharmacol., 1994, 46, 378-379.
235. Mistry, A.; Glud, S.Z.; Kjems, J.; Randel, J.; Howard, K.A.; Stolnik, S.; Illum, L. Effect of physicochemical properties on intranasal nanoparticle transit into murine olfactory epithelium. J. Drug Target., 2009, 17(7), 543-552.
236. Gao, X.; Tao, W.; Lu, W.; Zhang, Q.; Zhang, Y.; Jiang, X.; Fu, S. Lectinconjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials, 2006, 27(18), 3482-3490.
237. Wang, X.; Chi, N.; Tang, X. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur. J. Pharm. Biopharm., 2008, 70, 735-740.
238. Zhang, Q.Z.; Zha, L.S.; Zhang, Y.; Jiang, W.M.; Lu, W.; Shi, Z.Q.; Jiang, X.G.; Fu, S.K. The brain targeting efficiency following nasally applied MPEG-PLA nanoparticles in rats. J. Drug Target., 2006, 14, 281-290.
239. Betbeder, D.; Sperandio, S.; Latapie, J.P.; de Nadai, J.; Etienne, A.; Zajac, J.M.; Frances, B. Biovector (tm) nanoparticles improve antinociceptive efficacy of nasal morphine. Pharm. Res., 2000, 17, 743-748.
240. Huang, Y.; Donovan, M.D. Microsphere transport pathways in the rabbit nasal mucosa. Int. J. Pharm. Adv., 1996, 1, 298-309.
241. Wang, Y.-Y.; Lai, S.K.; Suk, J.S.; Pace, A.; Cone, R.; Hanes, J. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that Slip. Through the human mucus barrier. Angew. Chem. Int. Ed. Engl., 2008, 47, 9726-9729.
242. Bhavna, S.V.; Ali, M.; Baboota, S.; Ali, J. Preparation and characterization of chitosan nanoparticles for nose to brain delivery of a cholinesterase inhibitor. Indian J. Pharm. Sci., 2007, 69, 712-713.
243. Lai, S.K.; O'Hanlon, D.E.; Harrold, S.; Man, S.T.; Wang, Y.Y.; Cone, R.; Hanes, J. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 1482-1487.
244. Gao, X.; Wu, B.; Zhang, Q.; Chen, J.; Zhu, J.; Zhang, W.; Rong, Z.; Chen, H.; Jiang, X. Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. J. Control. Release, 2007, 121, 156-167.
245. Gao, X.; Chen, J.; Tao, W.; Zhu, J.; Zhang, Q.; Chen, H.; Jiang, X. UEA Ibearing nanoparticles for brain delivery following intranasal administration. Int. J. Pharm., 2007, 340, 207-215.
246. Jain, R.; Nabar, S.; Dandekar, P.; Patravale, V. Micellar nanocarriers: potential nose-to-brain delivery of zolmitriptan as novel migraine therapy. Pharm. Res., 2010, 27(4), 655-664.
247. Jain, R.; Nabar, S.; Dandekar, P.; Hassan, P.; Aswal, V.; Talmon, Y.; Shet, T.; Borde, L.; Ray, K.; Patravale, V. Formulation and evaluation of novel micellar nanocarrier for nasal delivery of sumatriptan. Nanomedicine (Lond)., 2010, 5(4), 575-587.
248. Zhang, Q.; Jiang, X.; Jiang, W.; Lu, W.; Su, L.; Shi, Z. Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. Int. J. Pharm., 2004, 275(1-2), 85-96.
249. Sharma, G.; Mishra, A.K.; Mishra, P.; Misra, A. Intranasal cabergoline: pharmacokinetic and pharmacodynamic studies. AAPS PharmSciTech., 2009, 10(4), 1321-1330.
250. Kumar, M.; Misra, A.; Mishra, A.K.; Mishra, P.; Pathak, K. Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting. J. Drug Target., 2008, 16(10), 806-814.
251. Vyas, T.K.; Babbar, A.K.; Sharma, R.K.; Singh, S.; Misra, A. Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. AAPS PharmSciTech., 2006, 7(1), E8.
252. Vyas, T.K.; Babbar, A.K.; Sharma, R.K.; Singh, S.; Misra, A. Intranasal mucoadhesive microemulsions of clonazepam: preliminary studies on brain targeting. J. Pharm. Sci., 2006, 95(3), 570-580.
253. Kumar, M.; Misra, A.; Babbar, A. K.; Mishra, A. K.; Mishra, P.; Pathak, K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int. J. Pharm., 2008, 358(1-2), 285-291.
254. Vyas, T.K.; Babbar, A.K.; Sharma, R.K.; Misra, A. Intranasal mucoadhesive microemulsions of zolmitriptan: preliminary studies on brain-targeting. J. Drug Target., 2005, 13(5), 317-324.
255. Alany, R.G.; Rades, T.; Nicoll, J.; Tucker, I.G.; Davies, N.M. W/O microemulsions for ocular delivery: evaluation of ocular irritation and precorneal retention. J. Control. Release, 2006, 111(1-2), 145-152.
256. Liwarska-Bizukojc, E.; Miksch, K.; Malachowska-Jutsz, A.; Kalka, J. Acute toxicity and genotoxicity of five selected anionic and nonionic surfactants. Chemosphere, 2005, 58(9), 1249-1253.
257. Moreno, M.A.; Ballesteros, M.P.; Frutos, P. Lecithin-based oil-in-water microemulsions for parenteral use: pseudoternary phase diagrams, characterization and toxicity studies. J. Pharm. Sci., 2003, 92(7), 1428-1437.
258. Palamakula, A.; Khan, M.A.; Evaluation of cytotoxicity of oils used in coenzyme Q10 Self-Emulsifying Drug Delivery Systems (SEDDS). Int. J. Pharm., 2004, 273, 63-73.
259. Quellet, C.; Eicke, H.F.; Sager, W. Formation of microemulsion-based gelatin gels. J. Phys. Chem., 1991, 95(14), 5642-5655.
260. Pisal, S.; Shelke, V.; Mahadik, K.; Kadam, S. Effect of organogel components on in vitro nasal delivery of propranolol hydrochloride. AAPS PharmSciTech, 2004, 5(4), e63.
261. Shelke, R.R.; Devarajan, P.V. Aqua Triggered In-situ gelling microemulsion for nasal delivery. Indian J. Pharm. Sci., 2007, 69, 726-727.